Literature DB >> 2552762

Leukotriene (LT) receptor antagonists. Heterocycle-linked tetrazoles and carboxylic acids. LY203647.

W S Marshall1, S K Sigmund, C A Whitesitt, S L Lifer, C R Roman, L E Rinkema, R A Hahn, J H Fleisch.   

Abstract

LY171883, 1-[2-hydroxy-3-propyl-4-[4-(1H-tetrazol-5-yl)butoxy]phenyl] ethanone, is an orally active antagonist of LTD4- and LTE4-induced responses in a variety of test systems. We prepared a new series of LT antagonists based on a proposed model of LY171883 binding to the LTE4 receptor in which the n-propyl and tetrazole moieties of LY171883 occupy those parts of the receptor to which the C1-C5 chain and the cysteinyl carboxyl of LTE4 bind, respectively. The new compounds have an acidic function corresponding to the glycine carboxyl of LTD4 linked through a heterocyclic group which is proposed to bind to the LTD4 receptor where the cysteinyl glycine amide bond of LTD4 binds. LY203647, 1-[2-hydroxy-3-propyl-4-[4-[2-[4-(1H-tetrazol-5-yl)butyl]-2H- tetrazol-5-yl]butoxy]phenyl] ethanone, showed good LTD4 antagonist activity with a suitable pharmacologic and toxicologic profile and has been chosen for clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2552762     DOI: 10.1007/BF01972807

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  2 in total

1.  Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters.

Authors:  J M VAN ROSSUM
Journal:  Arch Int Pharmacodyn Ther       Date:  1963

2.  Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives.

Authors:  W S Marshall; T Goodson; G J Cullinan; D Swanson-Bean; K D Haisch; L E Rinkema; J H Fleisch
Journal:  J Med Chem       Date:  1987-04       Impact factor: 7.446

  2 in total
  1 in total

1.  OVID and SUPER: two overlap programs for drug design.

Authors:  R B Hermann; D K Herron
Journal:  J Comput Aided Mol Des       Date:  1991-12       Impact factor: 3.686

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.